Efficacy of Vedolizumab (VDZ) by Disease Extension in Ulcerative Colitis (UC)

被引：0
|
作者：
Michetti, Pierre [1 ,2 ]
Braegger, Fiona [3 ]
Kempf, Christian [3 ]
Allez, Matthieu [4 ]
机构：
[1] CHU Vaudois, Gastroenterol La Source Beaulieu, Lausanne, Switzerland
[2] CHU Vaudois, Div Gastroenterol, Lausanne, Switzerland
[3] Takeda Pharmaceut Int AG, Zurich, Switzerland
[4] Univ Paris 07, Hop St Louis, AP HP, Dept Gastroenterol & Hepatol,INSERM,UMRS 1160, Paris, France
来源：
SWISS MEDICAL WEEKLY | 2018年 / 148卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
G38
引用
收藏
页码：22S / 22S
页数：1
相关论文
共 50 条
  • [31] Current position on Vedolizumab for ulcerative colitis and Crohn's disease
    Schreiber, S.
    Dignass, A. U.
    Hartmann, H.
    Kruis, W.
    Rogler, G.
    Siegmund, B.
    Stallmach, A.
    Witte, C.
    Bokemeyer, B.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (06): : 591 - 602
  • [32] Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis
    Narula, Neeraj
    Wong, Emily C. L.
    Marshall, John K.
    Colombel, Jean-Frederic
    Dulai, Parambir S.
    Reinisch, Walter
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (07) : 1588 - +
  • [33] Long-Term Efficacy of Vedolizumab Therapy for Patients With Ulcerative Colitis
    Feagan, Brian
    Kaser, Arthur
    Smyth, Michael
    Panaccione, Remo
    Sankoh, Serap
    Abhyankar, Brihad
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S477 - S478
  • [34] Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis
    Hagan, Matilda
    Cross, Raymond K.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (09) : 1473 - 1479
  • [35] Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?
    Gilroy, Leah
    Allen, Patrick B.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 163 - 172
  • [36] EFFICACY, SAFETY AND MUCOSAL HEALING OF EARLY VERSUS LATE USE OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY
    Vermeire, Severine
    Lowenberg, Mark
    Ferrante, Marc
    Bossuyt, Peter
    Hoentjen, Frank
    Franchimont, Denis
    Palatka, Karoly
    Peeters, Harald
    Baert, Filip J.
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2021, 160 (06) : S91 - S92
  • [37] The Efficacy of Vedolizumab, an alpha 4 beta 7 Integrin Antibody, in Crohn's Disease and Ulcerative Colitis
    Kim, Eun Sun
    INTESTINAL RESEARCH, 2013, 11 (04) : 325 - 326
  • [38] Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis
    D'Haens, Geert
    Rosario, Maria
    Polhamus, Daniel
    Dirks, Nathanael L.
    Chen, Chunlin
    Kisfalvi, Krisztina
    Agboton, Christian
    Vermeire, Severine
    Feagan, Brian G.
    Sandborn, William J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (04) : 403 - 412
  • [39] Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease
    Rosario, Maria
    French, Jonathan L.
    Dirks, Nathanael L.
    Sankoh, Serap
    Parikh, Asit
    Yang, Huyuan
    Danese, Silvio
    Colombel, Jean-Frederic
    Smyth, Michael
    Sandborn, William J.
    Feagan, Brian G.
    Reinisch, Walter
    Sands, Bruce E.
    Sans, Miguel
    Fox, Irving
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (08): : 921 - 929
  • [40] A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis
    Peyrin-Biroulet, L.
    Arkkila, P.
    Armuzzi, A.
    Atreya, R.
    Danese, S.
    Ferrante, M.
    Guardiola, J.
    Jahnsen, J.
    Louis, E.
    Lukas, M.
    Reinisch, W.
    Roblin, X.
    Smith, P. J.
    Kwon, T. S.
    Kim, J. Y.
    Yoon, S. W.
    Kim, D. H.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I1116 - I117
12345